Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Pain|April 16, 1998
Sympathetic nerve activity after acupuncture in humansStein Knardahl, Mikael Elam, Bengt Olausson, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|March 13, 2012
A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorderAllan H Young, Susan L McElroy, Bengt Olausson, et al.
Human Psychopharmacology|December 7, 2011
Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studiesDan J Stein, Borwin Bandelow, Charles Merideth, et al.
International Clinical Psychopharmacology|October 1, 2010
Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trialMartin A Katzman, Olga Brawman-Mintzer, Efren B Reyes, et al.
The Journal of Clinical Psychiatry|February 4, 2010
A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I)Allan H Young, Susan L McElroy, Michael Bauer, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|January 21, 2015
Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapyHans-Jürgen Möller, Koen Demyttenaere, Bengt Olausson, et al.
The Journal of Clinical Psychiatry|February 4, 2010
A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II)Susan L McElroy, Richard H Weisler, William Chang, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 11, 2014
Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressantEduard Vieta, Michael E Thase, Dieter Naber, et al.
Pageof 1